NEW YORK, May 6, 2026
Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib) featuring updated clinical efficacy data in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The application includes extended follow-up data from the pivotal TRUST-I and TRUST-II clinical studies and has been assigned an FDA target action date of January 4, 2027, marking another major regulatory milestone for the company’s precision oncology program.
The updated submission includes additional data supporting the long-term clinical benefit of IBTROZI in both treatment-naïve and previously treated ROS1-positive NSCLC patients. According to Nuvation Bio, the supplemental filing fulfills an FDA post-marketing commitment intended to strengthen efficacy information included in the product’s prescribing label. The latest clinical findings further reinforce the therapy’s growing position within the competitive targeted lung cancer treatment landscape.
IBTROZI Demonstrates Extended Clinical Benefit in ROS1+ NSCLC
Nuvation Bio reported that updated data from the TRUST-I and TRUST-II studies demonstrated encouraging long-term treatment outcomes among patients receiving IBTROZI therapy. In treatment-naïve patients enrolled in the TRUST-I study, the investigational therapy achieved a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) of 49.6 months, representing more than four years of sustained therapeutic benefit.
The company also reported that patients previously treated with tyrosine kinase inhibitors (TKIs) in the TRUST-II study demonstrated a median duration of response approaching 20 months, further supporting the therapy’s potential effectiveness in difficult-to-treat patient populations. Importantly, Nuvation Bio confirmed that the safety profile remained consistent with previous clinical findings, with no new safety signals identified during the extended follow-up period.
Advertisement
Many patients reportedly remained on therapy for prolonged periods without disease progression, highlighting the potential durability and tolerability of IBTROZI in advanced ROS1-positive lung cancer treatment. The updated findings were recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, reinforcing growing clinical interest in next-generation ROS1 inhibitor therapies.
FDA Review Strengthens Precision Oncology Expansion
Nuvation Bio Founder, President, and Chief Executive Officer Dr. David Hung stated that the updated clinical data support the company’s belief that IBTROZI may become a new standard of care for advanced ROS1-positive NSCLC. He emphasized that the combination of extended progression-free survival, long-term duration of response, and consistent safety findings could provide physicians and patients with increased confidence when selecting treatment strategies for ROS1-driven lung cancer.
The FDA granted full approval to IBTROZI in June 2025 for adult patients with locally advanced or metastatic ROS1-positive NSCLC across multiple lines of therapy. Since approval, the therapy has also expanded internationally, receiving regulatory approvals in Japan and China while progressing through additional global regulatory review processes. In March 2026, Nuvation Bio and its development partner Eisai announced that the European Medicines Agency validated the Marketing Authorisation Application for taletrectinib under the standard review timeline.
ROS1+ Lung Cancer Remains a Critical Oncology Challenge
Each year, more than one million individuals worldwide are diagnosed with non-small cell lung cancer, the most common form of lung cancer globally. Approximately 2% of NSCLC patients are estimated to carry ROS1-positive disease, a molecular subtype frequently associated with aggressive progression and central nervous system metastases. According to Nuvation Bio, nearly 35% of newly diagnosed metastatic ROS1-positive patients already present with brain metastases at diagnosis.
IBTROZI is designed as a next-generation ROS1 inhibitor with strong central nervous system activity intended to improve treatment outcomes in patients with metastatic disease. The company continues to advance multiple clinical studies within the TRUST program, including ongoing Phase 2 and Phase 3 trials evaluating the therapy in early-stage and treatment-naïve NSCLC populations across global markets.
As precision medicine and biomarker-driven oncology therapies continue reshaping cancer treatment strategies worldwide, Nuvation Bio remains focused on expanding its targeted oncology portfolio while advancing therapies capable of addressing difficult-to-treat cancers through next-generation molecular approaches.
Source: Nuvation Bio press release
